Natera stock trades at EUR 357.85 with a minus 294.6 P/ E

Published on 10/12/2026 at 15:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 752.75 million in the second quarter, up 37.70 percent. Natera stock stood at EUR 357.85 on October 12, 2026 versus EUR 356.80.

Key points in brief

Natera stock stood at EUR 357.85 at Lang & Schwarz on October 12, 2026 at 3:37 p.m. CEST, versus the Xetra close of EUR 356.80 on October 9, 2026.
Natera reported USD 752.75 million in second-quarter 2026 revenue, up 37.70 percent year over year.
MarketBeat listed a P/E ratio of minus 294.6, USD 57.2 billion in market capitalization and a Moderate Buy consensus with a USD 353.45 average target.
The next earnings report is expected on November 5, 2026, after the market close.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) stood at EUR 357.85 at Lang & Schwarz on October 12, 2026 at 3:37 p.m. CEST, or plus 0.29 percent versus the Xetra close of EUR 356.80 on October 9, 2026. MarketBeat reported a P/E ratio of minus 294.6 on October 10, 2026, putting valuation alongside the live euro quote.

Price remains below the yearly high

The primary Nasdaq listing was trading at USD 399.12 on October 12, 2026 at 9:45 a.m. ET. Its 52-week range was USD 167.99 to USD 437.41, leaving the US quote USD 38.29 below the high and USD 232.83 above the low.

Natera's market capitalization was USD 57.2 billion on October 12, 2026. The company remains a diagnostics business covering reproductive health, oncology and organ transplantation, with molecular testing products including Panorama and Signatera.

Revenue growth versus current valuation

MarketBeat reported USD 752.75 million in revenue for the second quarter of 2026, up 37.70 percent from the same quarter a year earlier. The quarter also brought a GAAP net loss of USD 66.97 million, compared with a USD 100.94 million loss in the prior-year quarter, according to Markets Insider on October 7, 2026.

MarketBeat listed 16 buy ratings, two strong-buy ratings, four hold ratings and one sell rating, producing a Moderate Buy consensus across 23 research firms. The average 12-month target was USD 353.45, below the October 12 Nasdaq quote of USD 399.12.

Comparison with peers

Natera (NASDAQ, USD): minus 0.40 percent, P/E minus 292.6, market capitalization USD 57.2 billion

Exact Sciences (NASDAQ, USD): 0.00 percent, P/E minus 188.6, market capitalization USD 20.0 billion

Guardant Health (NASDAQ, USD): minus 0.67 percent, P/E minus 47.8, market capitalization USD 22.3 billion

Next report arrives November 5

Gekko lists November 5, 2026, after the market close, as Natera's next expected earnings date. Its model cites consensus estimates of a USD 0.22 loss per share and USD 707.9 million in revenue for that report.

Trading levels and valuation

The current euro quote is EUR 357.85 at Lang & Schwarz, while the Nasdaq quote was USD 399.12 at 9:45 a.m. ET. The different currencies and venues should be read separately when comparing the live market levels.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.